Lido Advisors
REGN icon

Lido Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Lido Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.26M Sell
11,647
-92
-0.8% -$62.6K 0.02% 417
2026
Q1 		$9.07M Sell
11,739
-1,678
-13% -$1.28M 0.03% 335
2025
Q4 		$8.67M Buy
13,417
+1,271
+10% +$863K 0.03% 346
2025
Q3 		$6.83M Buy
12,146
+6,474
+114% +$3.66M 0.02% 374
2025
Q2 		$2.98M Buy
5,672
+1,464
+35% +$817K 0.01% 491
2025
Q1 		$2.67M Buy
4,208
+1,894
+82% +$1.3M 0.01% 477
2024
Q4 		$1.65M Buy
2,314
+201
+10% +$169K 0.01% 576
2024
Q3 		$2.22M Buy
2,113
+178
+9% +$198K 0.01% 447
2024
Q2 		$2.03M Buy
1,935
+77
+4% +$74.6K 0.01% 443
2024
Q1 		$1.79M Buy
1,858
+178
+11% +$169K 0.01% 456
2023
Q4 		$1.48M Buy
1,680
+229
+16% +$189K 0.01% 492
2023
Q3 		$1.19M Sell
1,451
-658
-31% -$517K 0.01% 491
2023
Q2 		$1.52M Buy
2,109
+695
+49% +$536K 0.01% 426
2023
Q1 		$1.16M Buy
1,414
+616
+77% +$465K 0.01% 440
2022
Q4 		$576K Buy
798
+153
+24% +$113K 0.01% 546
2022
Q3 		$444K Sell
645
-12
-2% -$7.55K 0.01% 584
2022
Q2 		$388K Sell
657
-226
-26% -$147K 0.01% 627
2022
Q1 		$616K Buy
883
+228
+35% +$144K 0.01% 537
2021
Q4 		$413K Sell
655
-86
-12% -$52.9K ﹤0.01% 685
2021
Q3 		$448K Buy
741
+110
+17% +$68.3K 0.01% 627
2021
Q2 		$353K Sell
631
-329
-34% -$167K ﹤0.01% 654
2021
Q1 		$455K Buy
960
+411
+75% +$200K 0.01% 529
2020
Q4 		$265K Sell
549
-93
-14% -$50.2K 0.01% 665
2020
Q3 		$359K Buy
642
+235
+58% +$142K 0.01% 444
2020
Q2 		$254K Buy
+407
New +$231K 0.01% 493
2019
Q3 		– Sell
-889
Closed -$278K – 606
2019
Q2 		$278K Buy
889
+11
+1% +$3.66K 0.02% 440
2019
Q1 		$360K Sell
878
-11
-1% -$4.53K 0.02% 346
2018
Q4 		$332K Buy
+889
New +$325K 0.03% 287

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Lido Advisors's REGN Position: Q2 2026 in Review

Lido Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 0.78% in Q2 2026, selling an estimated $62.6K and leaving 11,647 shares worth $7.26M. The position accounts for 0.02% of the portfolio, ranked #417.

Lido Advisors first reported a position in REGN in Q4 2018 and has held it in 28 quarters since. The position peaked at $9.07M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Lido Advisors held 11,647 shares of Regeneron Pharmaceuticals worth $7.26M as of Q2 2026.
  • Lido Advisors sold 92 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $62.6K.
  • Regeneron Pharmaceuticals made up 0.02% of Lido Advisors's portfolio in Q2 2026, its #417 holding.
  • Lido Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 28 quarters since.
  • Lido Advisors's Regeneron Pharmaceuticals position peaked at $9.07M in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.